Celgene, Mayo Clinic and GV-backed Evelo has added $47.5m to its coffers, seven months after closing a $50m series B round.
Evelo Biosciences, a US-based microbial therapeutics developer backed by pharmaceutical firm Celgene and medical practice and research group Mayo Clinic, has raised $47.5m in funding according to a regulatory filing.
Founded in 2014, Evelo Biosciences emerged out of incubator and venture capital firm Flagship Pioneering, and is working on a new class of medication known as monoclonal microbials which exploit naturally occurring microbes in the human microbiome.
The company is targeting a wide range of conditions from various cancers to…
